Independent Consultant. Public health research, data analysis, and commentary on the global provision of sexual and reproductive health and rights; telemedicine and self-managed medical abortion; ethics, policy and payment. Perspective matters.
Once a senior executive at one of the world’s largest abortion providers, Kevin Duffy is now exposing his former industry: written by Robert Colquhoun, Director of International Campaigns at 40 Days for Life. Day 41: a publication of 40 Days for Life. For many months, Kevin Duffy felt God pricking his conscience. He had been... Continue Reading →
Data obtained from five NHS Ambulance Trusts in England, show that emergency ambulance responses for complications arising after a medical abortion are three times higher for women using pills-by-post at home, compared to those who have their medical abortion in a clinic. Using our rights under the Freedom of Information Act, we asked each of... Continue Reading →
BPAS has reported that its abortion services are “under considerable pressure” and that the number of calls it has been receiving increased by about a third in the six months March to September this year. During the same period our volunteers were making mystery client calls to BPAS and MSI Reproductive Choices, and we found... Continue Reading →
Did you know that the Government and Abortion Providers routinely under report the rate of complications caused by abortion pills? Our freedom of information investigation reveals that less than 1-in-5 complications are being reported. DHSC Under Report. The official DHSC statistics for 2020 show a 1.1% complication rate for all medical abortions and only 0.3%... Continue Reading →
Medical abortion doesn't always work; it is well established that MA has an expected treatment failure rate of about 6%. Which means that as many as 1-in-17 pregnant women using abortion pills will subsequently need hospital treatment for complications arising from an incomplete abortion. Ranbaxy (UK) Limited is the manufacturer of Medabon, the mifepristone/misoprostol combination... Continue Reading →
Data published by the Office of National Statistics, show clearly that the increasing gap between conceptions and births is due to the increasing number of abortions. The ONS notes: "Prior to 1969, the first full year for which abortions data were available, the number of conceptions was equivalent to the number of births." Source: Office... Continue Reading →
We consider the possibility that the mere experience of pain, without the capacity for self reflection, is morally significant. We believe that fetal pain does not have to be equivalent to a mature adult human experience to matter morally, and so fetal pain might be considered as part of a humane approach to abortion. Derbyshire... Continue Reading →
A total of 4.1% of all medical abortions done at less than 12 weeks gestational age were incomplete and required surgical care in the form of a vacuum curettage procedure. Carlsson, I., Breding, K. & Larsson, PG. Complications related to induced abortion: a combined retrospective and longitudinal follow-up study. BMC Women's Health 18, 158 (2018). https://doi.org/10.1186/s12905-018-0645-6
Gynuity Health Projects, a pro-abortion activist organisation, recently published results from its own study into the safety and efficacy of telemedicine abortion. Two key findings are: Six percent of women using abortion pills at home, subsequently needed hospital treatment because of complications related to the abortion, a rate of 1-in-17.Four percent of women using abortion... Continue Reading →
In its SmPC (summaries of product characteristics), Ranbaxy states that there is a non-negligible risk of medical abortion treatment failure, as follows: The non-negligible risk of failure, which occurs in 4.5 to 7.8% of the cases, makes the follow-up visit mandatory in order to check that abortion is complete.The patient should be informed that surgical... Continue Reading →
Percuity 